[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506177":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":37,"responsibleParty":77,"collaborators":20,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":20,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":20,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":40,"whyStopped":20,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Shanghai Jiao Tong University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CLAGE-VEN-RIC-Conditioning","EXPERIMENTAL","Cladribine: 5mg\u002Fm2 day -21 to d -17 cytarabine: 1g\u002Fm2 day -21- to d -17 etoposide: 100mg\u002Fm2 day -17 to -15 venetoclax: 100mg day-21; 200mg day -20, 400mg day -19 to day-3 Fludarabine: 30mg\u002Fm2 day -7 to -3 Busulfan: 3.2mg\u002Fkg day -6 to -5 Melphalan: 50mg\u002Fm2 day -4 to -3. or Fludarabine 30mg\u002Fm2 day -7 to -3 Total marrow irradiation day-5 to -3 PBSC: day 0\n\nConditioning regimen cane delayed to in patients with ongoing active infection or work-up of donors after CLAGE-VEN chemotherapy based on clinicians' decision. Patients receiving all-HSCT in cytopenia are classified as sequential while patients with recovered CBC are considered as bridging transplantation.",[13],"Drug: CALGE-VEN- RIC-conditioning",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","CALGE-VEN- RIC-conditioning","Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Chun Wang","Shanghai Zhaxin Integrated Traditional Chinese and Western Medicine Hospital","STUDY_DIRECTOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Jiong HU","CONTACT","86-21-64370045","601878","hj10709@rjh.com.cn",{"name":34,"role":29,"phone":35,"phoneExt":20,"email":36},"Jieling Jiang","+8613311986505","jiangjieling66@hotmail.com",[38,58,68],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Blood & Marrow Transplantation Center, RuiJin Hospital","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":47,"coordinates":48},"Point",[49,50],121.45806,31.22222,{"lat":50,"lon":49},[53,55],{"name":54,"role":29,"phone":30,"phoneExt":20,"email":32},"Jiong HU, M.D.,",{"name":56,"role":29,"phone":30,"phoneExt":20,"email":57},"Ling Wang, M.D.,","cclingjar@163.com",{"facility":59,"status":40,"city":41,"state":20,"zip":20,"country":44,"countryCode":45,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"Department of Hematology, Shanghai No 6 Hospital",{"type":47,"coordinates":61},[49,50],{"lat":50,"lon":49},[64],{"name":65,"role":29,"phone":66,"phoneExt":20,"email":67},"Chunkang Chang","86-21-64369181","changchunkang@sjtu.edu.cn",{"facility":69,"status":40,"city":41,"state":20,"zip":20,"country":44,"countryCode":45,"cosmosGeoPoint":70,"geoPoint":72,"contacts":73},"Shanghai ZhaXin Hospital",{"type":47,"coordinates":71},[49,50],{"lat":50,"lon":49},[74],{"name":23,"role":29,"phone":75,"phoneExt":20,"email":76},"13386259777","wangc@gobroadhealthcare.com",{"type":78,"investigatorFullName":28,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Head, Blood & Marrow Transplantation Center, Rui Jin Hospital","100506177","phase-2-chemotherapy-clage-ven-sequential-with-reduced-intensity-conditioning-for-refractory-acute-myelodi-leukemia-100506177",false,"NCT05870995","Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia","A Phase II Single Arm Study of Cladribine, Cytarabine, Etoposide and Venetoclax Sequential With Reduced Dose Conditioning of Fludarabine, Busulfan and Melphalan or Total Marrow Radiation for Refractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n* patients with refractory AML: no remission after 2 induction therapy, relapsed AML within 6 months of 1st CR, relapse AML fail to having CR after reinduction therapy, multiple relapse and refractory relapse AML\n* patients with \\>5% bone marrow blast by morphology or by LAIP flowcytometry at enrollment\n* patients with HLA-matched sibling donor, 9-10\u002F10 matched unrelated donor or haplo-identical family donor\n* patients without active infection\n* informed consent provided\n\nExclusion Criteria:\n\n* patients with abnormal liver function (enzyme \\>2N or bilirubin \\>2N)\n* patients with abnormal renal function (Scr \\>1.5N)\n* patients with poor cardiac function （EF\\\u003C45%）","ALL","16 Years","65 Years",{"count":91,"type":92},100,"ESTIMATED","INTERVENTIONAL",[95],"PHASE2","The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory acute myeloid leukemia (AML). In this study, the aim is to further evaluate the efficacy and feasibility of the protocol with modifications: 1) reduced dose of CLAGE; 2) Reduced intensity conditioning (RIC) regimen as fludarabine, busulfan and melphalan (MBF) or total marrow irradiation (TMI); 3) Venetoclax was added to the chemotherapy and conditioning regimen.",[98],"Refractory Leukemia",[100],"refractory AML, allogeneic stem cell transplantation","2025-02-14",{"date":103,"type":104},"2025-02-18","ACTUAL",{"date":106,"type":104},"2023-02-01",{"date":108,"type":92},"2026-09-01",{"name":5,"class":6},3]